New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 25, 2013
09:35 EDTIMUCImmunoCellular added to Focus List at Roth Capital
Roth Capital added ImmunoCellular to the Focus List following strong long-term survival data from the Ph I ICT-107 study in front-line glioblastoma. Shares are Buy rated with a $9 price target.
News For IMUC From The Last 14 Days
Check below for free stories on IMUC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
08:19 EDTIMUCLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use